BioSpace News Archive

AbbVie will announce its third-quarter 2022 financial results on Friday, October 28, 2022, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT.

Fresenius Kabi announced it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent Dotarem®.

Xenetic Biosciences, Inc., a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, announced the appointment of Allan Tsung, MD to its Scientific Advisory Board.

Nascent Biotech, Inc. announced that the Company has enrolled the first patient of the fifth and final cohort of its Phase I clinical trial to evaluate Pritumumab as a treatment for Primary and Metastatic Brain Cancers.

Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, launched commercial operations in Great Britain and shipped the first customer orders for Nuceiva®▼ last month.

Microbot Medical Inc., which continues to be committed to expanding its capabilities, announced the newest appointment to its Scientific Advisory Board, David C. Madoff, M.D. Dr. Madoff, Professor of Radiology and Medical Oncology, Vice Chair for Clinical Research and Section Chief of Interventional Radiology at Yale School of Medicine, has joined the Company’s esteemed SAB.

Thermo Fisher Scientific announced the addition of a new freezer to its ultra-low temperature green portfolio, the Thermo Scientific TDE Series -80°C Chest Freezer.

Adaptive Phage Therapeutics, Inc. announced that the Defense Health Agency has awarded an additional $5 million to support clinical development of APT’s adaptive bacteriophage therapy in treatment of diabetic foot osteomyelitis.

InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, announced the appointment of Jason Myers, Ph.D., and Carol Berry to the company’s Board of Directors.

atai Life Sciences N.V. will participate in in the following investor events & host a virtual R&D Day in October.